Načítá se...
S-1 in the treatment of pancreatic cancer
S-1 is an oral 5-fluorouracil (5-FU) prodrug, which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase, the key enzyme of 5-FU catabolism. Recently, two important studies on the clinical use of S-1 for pancreatic cancer have been reported from Japan....
Uloženo v:
| Vydáno v: | World J Gastroenterol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4223244/ https://ncbi.nlm.nih.gov/pubmed/25386059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i41.15110 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|